Figure 3.

Assessments of mice-bearing tumor with protein vaccine/mesenchymal stem cell (MSC) combined treatment. (a) The volumes of subcutaneous tumors from different treatment groups. The tumors in combined-treatment group were significantly smaller than that in other groups at day 21, and slightly increased at day 28. Even after 34 days, the signal intensity of planar γ-camera imaging remains weak in combined-treatment group (n = 6). (b) Representative macro-morphological images of pulmonary nodules from different treatment groups. The least number of tumor nodules were observed in the combined-treatment group. (c) Quantification of pulmonary nodules from control and treatment groups. A significant decrease was observed in the number of pulmonary nodules in the combined-treatment group when compared with other groups (n = 5). Error bars indicate SD. *P < 0.05, compared with control group.